Introduction：Basic information about CAS 165800-06-6|Zoledronic acid hydrate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Zoledronic acid hydrate |
|---|
| CAS Number | 165800-06-6 | Molecular Weight | 290.105 |
|---|
| Density | / | Boiling Point | 764ºC at 760 mmHg |
|---|
| Molecular Formula | C5H12N2O8P2 | Melting Point | 245 °C(dec.) |
|---|
| MSDS | ChineseUSA | Flash Point | 415.8ºC |
|---|
| Symbol |
GHS07 | Signal Word | Warning |
|---|
Names
| Name | Zoledronic acid hydrate |
|---|
| Synonym | More Synonyms |
|---|
Zoledronic acid hydrate BiologicalActivity
| Description | Zoledronic acid monohydrate is a third-generation, nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption, and also has antitumor activity. |
|---|
| Related Catalog | Signaling Pathways >>Autophagy >>AutophagyResearch Areas >>Cancer |
|---|
| In Vitro | Zoledronic acid monohydrate induces apoptosis in HGF and HaCaT cells at 0.5 μM, and causes cell death at 1-5 μM[1]. Zoledronic Acid (50, 100 μM) causes dose- and time-dependent apoptosis in CNE-2Z cells after treatment for 24, 48, and 72 h. Zoledronic Acid (50 μM) also increases the level of ROS, which is supposed to mediate Cl- currents activation in CNE-2Z cells. Furthermore, the apoptosis and chloride currents induced by Zoledronic Acid can be blocked by knocking down ClC-3 protein expression[2]. |
|---|
| References | [1]. Scheper M, et al. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. ibrogenesis Tissue Repair. 2010 Apr 1;3:6. [2]. Wang L, et al. The apoptotic effect of Zoledronic acid on the nasopharyngeal carcinoma cells via ROS mediated chloride channel activation. Clin Exp Pharmacol Physiol. 2018 Jun 8. |
|---|
Chemical & Physical Properties
| Boiling Point | 764ºC at 760 mmHg |
|---|
| Melting Point | 245 °C(dec.) |
|---|
| Molecular Formula | C5H12N2O8P2 |
|---|
| Molecular Weight | 290.105 |
|---|
| Flash Point | 415.8ºC |
|---|
| Exact Mass | 290.006897 |
|---|
| PSA | 181.96000 |
|---|
| Vapour Pressure | 1.53E-24mmHg at 25°C |
|---|
| InChIKey | FUXFIVRTGHOMSO-UHFFFAOYSA-N |
|---|
| SMILES | O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O |
|---|
| Storage condition | 2-8°C |
|---|
Safety Information
| Symbol |
GHS07 |
|---|
| Signal Word | Warning |
|---|
| Hazard Statements | H315-H319-H335 |
|---|
| Precautionary Statements | P305 + P351 + P338 |
|---|
| Hazard Codes | Xi |
|---|
| Risk Phrases | 36/37/38 |
|---|
| Safety Phrases | 26 |
|---|
| RIDADR | NONH for all modes of transport |
|---|
| HS Code | 2933290090 |
|---|
Customs
| HS Code | 2933290090 |
|---|
| Summary | 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Articles1
More Articles
| Caveolae as a target to quench autoinduction of the metastatic phenotype in lung cancer. J. Cancer Res. Clin. Oncol. 142 , 611-8, (2016) Mevalonate pathway inhibitors are potentially useful chemotherapeutic agents showing growth inhibition and pro-apoptotic effects in cancer cells. The effects of statins and bisphosphonates on cancer g... | |
Synonyms
| (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid,hydrate |
| Zoledronic acid monohydrate |
| Reclast |
| Zometa |
| [1-Hydroxy-2-(1H-imidazol-1-yl)-1,1-ethanediyl]bis(phosphonic acid) hydrate (1:1) |
| Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-, hydrate (1:1) |
| (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid hydrate |
| MFCD08448695 |
| Aclasta |
| 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid Monohydrate |
| [1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) hydrate (1:1) |
| Zoledronic acid hydrate |
| Zoledronic acid |
| Zoledronic acid (monohydrate) |
